•
Mar 31

Altria Q1 2025 Earnings Report

Altria posted solid results with EPS growth and reaffirmed its full-year guidance.

Key Takeaways

Altria delivered resilient first-quarter results, driven by strong performance in its smokeable products and oral tobacco segments, despite challenges from the e-vapor market and volume declines.

Adjusted EPS rose 6.0% year-over-year to $1.23.

Reported diluted EPS fell 47.9% due to a large non-cash impairment charge.

Smokeable segment adjusted OCI grew 2.7%, driven by higher pricing and cost controls.

Altria reaffirmed its full-year 2025 adjusted EPS growth target of 2% to 5%.

Total Revenue
$5.26B
Previous year: $5.58B
-5.7%
EPS
$1.23
Previous year: $1.15
+7.0%
Total Cigarette Share
45%
Previous year: 46.4%
-3.0%
Marlboro Retail Share
41%
Previous year: 42%
-2.4%
NJOY Retail Share
6.6%
Previous year: 4.2%
+57.1%
Gross Profit
$3.25B
Previous year: $3.28B
-0.9%
Cash and Equivalents
$4.73B
Previous year: $3.61B
+31.0%
Total Assets
$35.8B
Previous year: $36.5B
-2.0%

Altria

Altria

Altria Revenue by Segment

Altria Revenue by Geographic Location

Forward Guidance

Altria reaffirmed its 2025 full-year adjusted EPS growth forecast of 2% to 5%, assuming continued investment in smoke-free products and no return of ACE products.

Positive Outlook

  • Full-year adjusted EPS growth expected at 2% to 5%.
  • Strong cash returns to shareholders via dividends and buybacks.
  • Strategic investment in smoke-free alternatives.
  • Solid momentum in oral nicotine products (on!).
  • Cost savings initiatives expected to drive efficiencies.

Challenges Ahead

  • External environment remains dynamic with regulatory risks.
  • Potential impacts from illicit e-vapor market growth.
  • Tariff-related cost pressures on supply chain.
  • Reduced volumes in combustible segments driven by market declines.
  • No anticipated reentry of ACE e-vapor product in 2025.

Revenue & Expenses

Visualization of income flow from segment revenue to net income